page contents

BioXel Gears Up for IPO

BioXel Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, but the offering is valued up to $ 69.0 million. The company intends to list its shares on the Nasdaq under the symbol BTAI.

The underwriters for the offering are Barclays, UBS Investment Bank and BMO Capital Markets.

This is a clinical-stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.

The firm’s drug re-innovation ap…
24/7 Wall St.

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.